Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- NA
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Status
- RECRUITING
- Phase
- PHASE3
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Status
- RECRUITING
- Phase
- PHASE3
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
- Status
- RECRUITING
- Phase
- PHASE2
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Status
- RECRUITING
- Phase
- PHASE2
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
- Status
- RECRUITING
- Phase
- PHASE2
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE2